𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Fcγ receptor type IIIA genotype and response to tumor necrosis factor α–blocking agents in patients with rheumatoid arthritis

✍ Scribed by Alf Kastbom; Johan Bratt; Sofia Ernestam; Jon Lampa; Leonid Padyukov; Peter Söderkvist; Thomas Skogh

Publisher
John Wiley and Sons
Year
2007
Tongue
English
Weight
82 KB
Volume
56
Category
Article
ISSN
0004-3591

No coin nor oath required. For personal study only.

✦ Synopsis

Abstract

Objective

To determine whether a functional single‐nucleotide polymorphism in the gene encoding Fcγ receptor type IIIA (FcγRIIIA) correlates with the response to treatment with tumor necrosis factor α inhibitors in rheumatoid arthritis (RA).

Methods

The study population comprised 282 Swedish patients with RA in whom the therapeutic efficacy of conventional disease‐modifying antirheumatic drugs had been insufficient. Infliximab or etanercept treatment was initiated, and patients were evaluated after 3 months, using the American College of Rheumatology 20% improvement criteria (ACR20), the ACR50, and the ACR70 or the European League Against Rheumatism (EULAR) criteria. The chi‐square test was used to compare response rates across FcγRIIIA genotypes.

Results

No differences in genotype distribution were observed among nonresponders compared with ACR20 responders (P = 0.80), ACR50 responders (P = 0.56), or ACR70 responders (P = 0.91). Similar results were observed when analyzing infliximab and etanercept separately or when using the EULAR response criteria.

Conclusion

Unlike the findings of a previous study, the results of the current study suggest that the 158V/F polymorphism of FcγRIIIA is very unlikely to influence the clinical efficacy of infliximab or etanercept in patients with RA.

📜 SIMILAR VOLUMES

Fcγ receptor type IIIA polymorphisms inf
Fcγ receptor type IIIA polymorphisms influence treatment outcomes in patients with inflammatory arthritis treated with tumor necrosis factor α–blocking agents
✍ Zuhre Tutuncu; Arthur Kavanaugh; Nathan Zvaifler; Maripat Corr; Reena Deutsch; D 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 83 KB

## Abstract ## Objective To determine whether polymorphisms in Fcγ receptor type IIIA (FcγRIIIA) correlate with clinical efficacy in patients with rheumatoid arthritis (RA) and patients with psoriatic arthritis (PsA) being treated with tumor necrosis factor α (TNFα) inhibitors. ## Methods The st

B cell depletion may be more effective t
B cell depletion may be more effective than switching to an alternative anti–tumor necrosis factor agent in rheumatoid arthritis patients with inadequate response to anti–tumor necrosis factor agents
✍ Axel Finckh; Adrian Ciurea; Laure Brulhart; Diego Kyburz; Burkhard Möller; Silvi 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 199 KB 👁 2 views

## Abstract ## Objective Patients with rheumatoid arthritis (RA) in whom the response to anti–tumor necrosis factor (anti‐TNF) therapy is inadequate have several therapeutic options, such as switching to an alternative anti‐TNF agent or initiating B cell–depleting therapy with rituximab (RTX). Alt